Overview

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-31

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to learn if the medication atomoxetine can reduce freezing of gait in people with Parkinson's disease. The main questions it aims to answer is: Does atomoxetine reduce the frequency or severity of freezing of gait? What role does noradrenaline play in freezing of gait? Researchers will compare atomoxetine to a placebo to see if atomoxetine can improve freezing of gait in people with Parkinson's disease. Participants will: Visit the study site for measurements Take atomoxetine or placebo Perform walking assessments and undergo MRI Complete questionnaires about anxiety, stress, and quality of life

Phase:

PHASE3

Details

Lead Sponsor:

Radboud University Medical Center

Collaborators:

Macquarie University, Australia
University of Waterloo

Treatments:

Atomoxetine Hydrochloride